

5637 | 300105

XXXXXXXXXX

**Description**

5637 is a cell line derived from a 68-year-old male patient with metastatic melanoma. The cell line is characterized by a karyotype of 46,XY,t(17;1)(p11;p11). The cell line is highly tumorigenic and grows in DMEM supplemented with 10% FBS. The cell line is sensitive to treatment with BRAF inhibitors (vemurafenib) and MEK inhibitors (trametinib). The cell line is also sensitive to treatment with EGFR inhibitors (erlotinib) and PI3K inhibitors (alpelisib). The cell line is also sensitive to treatment with CDK4/6 inhibitors (palbociclib).

5637 is a cell line derived from a 68-year-old male patient with metastatic melanoma. The cell line is characterized by a karyotype of 46,XY,t(17;1)(p11;p11). The cell line is highly tumorigenic and grows in DMEM supplemented with 10% FBS. The cell line is sensitive to treatment with BRAF inhibitors (vemurafenib) and MEK inhibitors (trametinib). The cell line is also sensitive to treatment with EGFR inhibitors (erlotinib) and PI3K inhibitors (alpelisib). The cell line is also sensitive to treatment with CDK4/6 inhibitors (palbociclib).

5637 is a cell line derived from a 68-year-old male patient with metastatic melanoma. The cell line is characterized by a karyotype of 46,XY,t(17;1)(p11;p11). The cell line is highly tumorigenic and grows in DMEM supplemented with 10% FBS. The cell line is sensitive to treatment with BRAF inhibitors (vemurafenib) and MEK inhibitors (trametinib). The cell line is also sensitive to treatment with EGFR inhibitors (erlotinib) and PI3K inhibitors (alpelisib). The cell line is also sensitive to treatment with CDK4/6 inhibitors (palbociclib).

**Organism** HOMO SAPIENS

**Tissue** SKIN

**Disease** MELANOMA

**Metastatic site** SKIN (METASTATIC)

**Applications** CELL CULTURE, TUMOR MODEL

XXXXXXXXXX

**Age** 68

**Gender** MALE

**Ethnicity** CAUCASIAN

**Morphology** CLUSTERING




**Cell type** EPITHELIAL

**Growth properties** ADHESIVE





Product sheet

5637  | 300105














Citation	5637 (   300105)
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_0126
GMO Status	



Isoenzymes	
Tumorigenic	
Products	IL-1, IL-6, G-CFS, GM-CSF, SCF
Ploidy status	
Karyotype	



Culture Medium	RPMI 1640  2.0   2.0  NaHCO3 (  820700a 
Supplements	
Dissociation Reagent	
Doubling time	24 
Subculturing	
Split ratio	



Product sheet




5637  | 300105

Storage Conditions




 -150 °C -196 °C 

 /  / HLA

Sterility

 (PCR)   


 HLA

- A\*: '11:01:01, '68:02:01
- B\*: '15:03:01, '55:02:01
- C\*: '01:02:01, '02:10:01
- DRB1\*: '01:02:01, '09:01:02G
- DQA1\*: '01:01:02, '03:02:01
- DQB1\*: '03:03:02, '05:01:01
- DPB1\*: '05:01:01  '13:01:01  '13:01:01 
- E: '01:03:02